Blommestein, H. M., Armstrong, N., Ryder, S., Deshpande, S., Worthy, G., Noake, C., . . . Al, M. J. (2015). Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene. Pharmacoeconomics.
Citação norma ChicagoBlommestein, Hedwig M., et al. "Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated With Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission From Celgene." Pharmacoeconomics 2015.
MLA引文Blommestein, Hedwig M., et al. "Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated With Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission From Celgene." Pharmacoeconomics 2015.